D-Index & Metrics Best Publications
Microbiology
Australia
2022

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Microbiology D-index 102 Citations 38,071 448 World Ranking 78 National Ranking 3
Medicine D-index 107 Citations 41,378 554 World Ranking 2778 National Ranking 96

Research.com Recognitions

Awards & Achievements

2022 - Research.com Microbiology in Australia Leader Award

2016 - Fellow of the Australian Academy of Health and Medical Science

Overview

What is he best known for?

The fields of study he is best known for:

  • Internal medicine
  • Acquired immunodeficiency syndrome
  • Virus

Gregory J. Dore mainly investigates Hepatitis C, Hepatitis C virus, Internal medicine, Immunology and Virology. His research in Hepatitis C intersects with topics in Cirrhosis, Viral load, Transmission, Liver disease and Ribavirin. The study incorporates disciplines such as Alpha interferon and Pharmacology in addition to Ribavirin.

The various areas that Gregory J. Dore examines in his Hepatitis C virus study include Seroconversion, Disease burden, Public health and Intensive care medicine. His Internal medicine study integrates concerns from other disciplines, such as Surgery, Gastroenterology, Acquired immunodeficiency syndrome, Sofosbuvir and Coinfection. Gregory J. Dore interconnects Genotype, Incidence and Disease in the investigation of issues within Immunology.

His most cited work include:

  • IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. (1667 citations)
  • IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. (1667 citations)
  • Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study (981 citations)

What are the main themes of his work throughout his whole career to date?

His primary areas of investigation include Hepatitis C, Internal medicine, Hepatitis C virus, Virology and Immunology. His Hepatitis C research is multidisciplinary, relying on both Epidemiology, Viral load, Liver disease, Hepacivirus and Drug. His work in Internal medicine addresses issues such as Ribavirin, which are connected to fields such as Alpha interferon.

His Hepatitis C virus research incorporates elements of Incidence, Intensive care medicine, Transmission, Hepatocellular carcinoma and Genotype. Particularly relevant to Virus is his body of work in Virology. As part of his studies on Immunology, Gregory J. Dore frequently links adjacent subjects like Acquired immunodeficiency syndrome.

He most often published in these fields:

  • Hepatitis C (58.48%)
  • Internal medicine (56.30%)
  • Hepatitis C virus (50.08%)

What were the highlights of his more recent work (between 2017-2021)?

  • Internal medicine (56.30%)
  • Hepatitis C (58.48%)
  • Hepatitis C virus (50.08%)

In recent papers he was focusing on the following fields of study:

Gregory J. Dore spends much of his time researching Internal medicine, Hepatitis C, Hepatitis C virus, Incidence and Virology. His studies examine the connections between Internal medicine and genetics, as well as such issues in Gastroenterology, with regards to Dried blood spot. The Hepatitis C study which covers Hepatocellular carcinoma that intersects with Liver disease, Improved survival and Carcinoma.

Many of his research projects under Hepatitis C virus are closely connected to World health with World health, tying the diverse disciplines of science together. His Incidence research is multidisciplinary, incorporating elements of Treatment as prevention, Confidence interval, Hcv transmission, Prospective cohort study and Pediatrics. In his study, Venipuncture is strongly linked to Cohort study, which falls under the umbrella field of Viral load.

Between 2017 and 2021, his most popular works were:

  • Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection (217 citations)
  • Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial. (126 citations)
  • Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial. (126 citations)

In his most recent research, the most cited papers focused on:

  • Internal medicine
  • Acquired immunodeficiency syndrome
  • Virus

Hepatitis C, Hepatitis C virus, Internal medicine, Sofosbuvir and Cirrhosis are his primary areas of study. His work carried out in the field of Hepatitis C brings together such families of science as Ombitasvir, Dasabuvir, Ritonavir, Paritaprevir and Drug. His Hepatitis C virus study results in a more complete grasp of Virology.

His Virology research includes elements of Haplotype and DNA sequencing. His study in Internal medicine is interdisciplinary in nature, drawing from both Gastroenterology and Ribavirin. Gregory J. Dore focuses mostly in the field of Incidence, narrowing it down to matters related to Prospective cohort study and, in some cases, Men who have sex with men, Female sex, Survival analysis and Immunology.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy.

Vijayaprakash Suppiah;Max Moldovan;Golo Ahlenstiel;Thomas Berg.
Nature Genetics (2009)

2281 Citations

Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study

Sarah Blach;Stefan Zeuzem;Michael Manns;Ibrahim Altraif.
The Lancet Gastroenterology & Hepatology (2017)

1254 Citations

Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies.

J M Micallef;J M Kaldor;G J Dore.
Journal of Viral Hepatitis (2006)

1045 Citations

Epidemiology and natural history of HCV infection

Behzad Hajarizadeh;Jason Grebely;Gregory J. Dore.
Nature Reviews Gastroenterology & Hepatology (2013)

1029 Citations

Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: A meta-analysis and meta-regression†

Hla-Hla Thein;Hla-Hla Thein;Qilong Yi;Gregory J. Dore;Murray D. Krahn;Murray D. Krahn.
Hepatology (2008)

931 Citations

Estimating progression to cirrhosis in chronic hepatitis C virus infection.

Anthony J. Freeman;Gregory J. Dore;Matthew G. Law;Max Thorpe.
Hepatology (2001)

819 Citations

Hepatitis C Virus Treatment for Prevention Among People Who Inject Drugs: Modeling Treatment Scale-Up in the Age of Direct-Acting Antivirals

Natasha K. Martin;Peter Vickerman;Jason Grebely;Margaret Hellard.
Hepatology (2013)

528 Citations

Changes to AIDS dementia complex in the era of highly active antiretroviral therapy

Gregory J. Dore;Patricia K. Correll;Yueming Li;John M. Kaldor.
AIDS (1999)

473 Citations

Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis.

Hla-Hla Thein;Qilong Yi;Gregory J Dore;Murray D Krahn.
AIDS (2008)

468 Citations

Global burden of disease (GBD) for hepatitis C

Y Hutin;ME Kitler;GJ Dore;JF Perz.
JOURNAL OF CLINICAL PHARMACOLOGY , 44 (1) pp. 20-29. (2004) (2004)

465 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Gregory J. Dore

Margaret Hellard

Margaret Hellard

Burnet Institute

Publications: 195

Stefan Zeuzem

Stefan Zeuzem

Goethe University Frankfurt

Publications: 125

Peter Vickerman

Peter Vickerman

University of Bristol

Publications: 124

Matthew Hickman

Matthew Hickman

University of Bristol

Publications: 109

Jacob George

Jacob George

University of Sydney

Publications: 96

Heiner Wedemeyer

Heiner Wedemeyer

Hannover Medical School

Publications: 89

Mark S. Sulkowski

Mark S. Sulkowski

Johns Hopkins University School of Medicine

Publications: 87

Kazuaki Chayama

Kazuaki Chayama

Hiroshima University

Publications: 85

Zobair M. Younossi

Zobair M. Younossi

Inova Health System

Publications: 81

Lisa Maher

Lisa Maher

UNSW Sydney

Publications: 79

Vincent Soriano

Vincent Soriano

Hospital Universitario La Paz

Publications: 75

Jia-Horng Kao

Jia-Horng Kao

National Taiwan University

Publications: 75

Christoph Sarrazin

Christoph Sarrazin

Goethe University Frankfurt

Publications: 73

Jason Grebely

Jason Grebely

UNSW Sydney

Publications: 73

Andrew R. Lloyd

Andrew R. Lloyd

UNSW Sydney

Publications: 71

Jean-Michel Pawlotsky

Jean-Michel Pawlotsky

Université Paris Cité

Publications: 70

Trending Scientists

Paolo Giorgini

Paolo Giorgini

University of Trento

Virginia Dignum

Virginia Dignum

Umeå University

Ye Wu

Ye Wu

Tsinghua University

William E. Acree

William E. Acree

University of North Texas

Christopher M. Sorensen

Christopher M. Sorensen

Kansas State University

Yanna Nuli

Yanna Nuli

Shanghai Jiao Tong University

Andreas Wagner

Andreas Wagner

University of Zurich

Tadeusz J. Kawecki

Tadeusz J. Kawecki

University of Lausanne

Cleber Galvão

Cleber Galvão

Oswaldo Cruz Foundation

Yukihiko Kitamura

Yukihiko Kitamura

Osaka University

Marcio L. Rodrigues

Marcio L. Rodrigues

Federal University of Rio de Janeiro

Rodrigo Correa-Oliveira

Rodrigo Correa-Oliveira

Oswaldo Cruz Foundation

Moises A. Calderon

Moises A. Calderon

National Institutes of Health

Pavan Reddy

Pavan Reddy

University of Michigan–Ann Arbor

Teodora Gliga

Teodora Gliga

University of East Anglia

William C. Chapman

William C. Chapman

Washington University in St. Louis

Something went wrong. Please try again later.